Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2
Cabozantinib is a receptor tyrosine kinase inhibitor (TKI) with activity against a broad range of targets, including MET, RET, AXL, VEGFR2, FLT3, and c-KIT. Activity of cabozantinib towards a broad range of tumor models could be detected in several preclinical studies. Of note, cabozantinib decreases metastasis potential and tumor invasiveness when compared with placebo or agents that target VEGFR and have no activity against MET. Cabozantinib is clinically approved for the treatment of medullary thyroid cancer (MTC) and for renal cell cancer (RCC) in the second line. In MTC gain of function mutations, mutations of RET are central for tumorigenesis. Hereditary forms of MTC (MEN II) are caused by germline mutations of RET, in sporadic MTC up to 50% of cases RET mutations occur. Both MET and AXL have been described as mechanisms facilitating resistance against VEGFR-targeted tyrosine kinase therapy in clear cell RCC. Accordingly, cabozantinib has shown activity in RCC patients progressing after first-line VEGFR-TKI therapy in the pivotal METEOR trial. This phase III trial reported a benefit of 4.9 months in survival and an increase in response rate compared to standard everolimus over all patient subgroups. Of particular interest are the effects on patients with bone metastasis, which have a worse prognosis. In these patients, the beneficial effects of cabozantinib over everolimus were even more pronounced. Side effects of interest include diarrhea, hypertension, fatigue, and hand–foot syndrome.
KeywordsMultikinase-Inhibitor Renal cell cancer Medullary thyroid cancer MET AXL
- Direnzo MF et al (1995) Overexpression and simplification of the met/HGF receptor gene during the progression of colorectal-cancer. Clin Cancer Res 1(2):147–154Google Scholar
- Houldsworth J et al (1990) Gene amplification in gastric and esophageal adenocarcinomas. Can Res 50(19):6417–6422Google Scholar
- Nadal R, Mortazavi A, Stein M, Pal SK, Davarpanah N, Parnes HL, Ning YM, Cordes LM, Lin J, Bagheri M, Linderberg L, Berniger M, Steinberg SM, Moore T, Lancaster T, Aviles M, Costello R, Bottaro DP, Dahut WL, Apolo AB (2017) 846O Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Ann Oncol 28(suppl_5), 1 September 2017, mdx371.001Google Scholar
- Rankin EB, Giaccia AJ (2016) The receptor tyrosine kinase AXL in cancer progression. Cancers (Basel) 8(11)Google Scholar
- Schoffski P et al (2012) An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30(15)Google Scholar